A clinical trial of KP484
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
At a glance
- Drugs KP-484 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- 02 Nov 2017 According to a KemPharm media release, this study is anticipated to be initiated in 2018.
- 02 Nov 2017 According to a KemPharm media release, Investigational New Drug (IND) application has been approved.
- 22 Sep 2017 New trial record